Physician profile
Edwin J Whitney
NPI 1669563656
$30,484.79
in general payments reported to CMS, 2019-2025
19 companies · $859 in 2025
The $859 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $12K · 2021: $519 · 2022: $617 · 2023: $800 · 2024: $915 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,199 · Consulting Fee: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,199.44 |
| Consulting Fee | $375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $16,188.21 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $10,327.70 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $824.32 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $552.74 | 2021-2024 | Cycloset |
| Novo Nordisk INC | $483.47 | 2019-2024 | Wegovy |
| Janssen Pharmaceuticals, INC | $450.01 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $394.75 | 2023-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $277.82 | 2020-2022 | |
| Pfizer INC. | $182.58 | 2019 | |
| Alnylam Pharmaceuticals INC. | $155.65 | 2023-2025 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $144.82 | 2021-2024 | Lifevest |
| Lundbeck LLC | $124.99 | 2019 | |
| Merck Sharp & Dohme LLC | $88.54 | 2021-2024 | Verquvo |
| Amarin Pharma, INC. | $83.64 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $66.48 | 2019-2023 | Evkeeza, Praluent |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $56.33 | 2025 | Arexvy, Shingrix |
| Abbott Laboratories | $45.41 | 2022 | |
| Heartflow, INC. | $21.22 | 2025 | |
| Amgen INC. | $16.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Whitney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.